Fulgent Genetics 3Q2026 conference call and webcast - FULGENT GENETICS INC

Explicit Guidance:

• FY2026 Revenue: Reaffirmed guidance of $330–$340 million, representing 2.3%–5.4% year-over-year growth.
• FY2026 Revenue by Segment: Precision diagnostics estimated at $161–$165 million; Anatomic pathology at $146–$150 million; Biopharma services at $23–$25 million.
• FY2026 Margins: Non-GAAP gross margins expected in the mid-30% range; Non-GAAP operating margins expected in the low negative 20% range (improved from prior mid-negative 20% expectation).
• FY2026 Earnings Per Share: Non-GAAP loss expected of $1.65–$1.75 per share (improved from prior guidance of $2.22–$2.35), assuming 4.1 million shares repurchased year-to-date and no further repurchases.
• FY2026 Therapeutic Development CapEx: Expected investment of approximately $21 million to advance trials for FID-022 and FID-007.
• FY2026 Capital Expenditures: Estimated at $13 million.
• FY2026 Cash Position: Projected year-end cash, cash equivalents, restricted cash, and marketable securities of approximately $630 million (increased from prior $610 million forecast).

Business-Segment Outlook:

• Laboratory Services (Billing/RCM): Revenue cycle management transition is "pretty deep into the game" with significant customization progress; team expects to return to historical collection rates, though precise timing is not yet predictable. Sequential gross margin improvements are expected to continue as billing optimization drives revenue growth.
• Laboratory Services (AI): AI platform analyzed 255,000 slides in Q3; five additional AI applications planned for deployment in Q4 2026. Future growth driven by improved diagnostic consistency and pathologist productivity.
• Therapeutics (FID-007): Phase II majority complete; FDA end-of-Phase II meeting held in August; Phase III registration trial preparation is underway.
• Therapeutics (FID-022): Phase I dosing escalation ongoing; maximum tolerance dose (MTD) expected to be determined in the first half of 2027.
• M&A Integration: BACO Diagnostics and StrataDx integration continues to drive efficiency and cross-selling opportunities.

Market and Competitive Outlook:

• Regulatory (PAMA): Expectations are that the impact of the PAMA (Payment Reform Act) and clinical lab fee schedule changes will be minimal due to limited exposure of primary CPT codes to reimbursement reductions; viewed as not a material headwind.
• Therapeutic Market: FID-007 targets recurrence/metastatic head and neck squamous cell carcinoma patients with very few effective treatment options; FID-022 targets solid tumors (colon, pancreatic, ovarian, bile duct).
• AI Market: AI utilization scaling is expected to yield operating leverage and margin expansion as volumes grow.

Macro / Industry Outlook:

• Tax Refunds: A $112.3 million federal tax refund and interest (delayed due to IRS resource constraints) contributed significantly to Q3 cash position and improved the FY2026 cash forecast.
• IRS/Labor Market: Previous constraints at the IRS delaying tax refunds have eased, facilitating improved cash flow.

Strategic Initiatives:

• Capacity & Infrastructure: Investments targeted at laboratory infrastructure upgrades to enhance throughput capacity and strengthen competitive position.
• AI Infrastructure: Transitioned production environment to a new AI analysis platform to improve speed, reliability, and scalability; reduced processing times for high-volume applications.
• Clinical Pipeline: Advancing both laboratory testing capabilities and clinical study pipelines; aligning sales organization for expanded product menu.
• Share Repurchases: Approximately 75.6 million shares remain available for future repurchases; program assumes no further buybacks in current guidance model.

Risks and Headwinds to Outlook:

• Billing Transition Risks: While progress is encouraging, additional effort is needed to finalize RCM customizations; timing for full return to historical collection rates remains unpredictable.
• Guidance Variability: Actual results may differ due to risks, uncertainties, and changes in circumstances; management does not reconcile forward-looking non-GAAP measures to GAAP due to unpredictability of equity compensation, tax effects, and acquisition items.
• Clinical Progress: Therapeutic timelines depend on successful Phase III trial execution for FID-007 and MTD determination for FID-022.
• Seasonality: While business is somewhat shielded, seasonality in pathology, rare disease, and biopharma services remains a factor.

Management Tone on the Future:

• Confidence Level: Positive and cautious optimism. Management expresses being "pleased with momentum," "encouraged by clinical progress," and "proud of operational progress."
• Guidance Changes: EPS guidance improved (narrowed loss range) and cash forecast raised ($10M increase). Revenue guidance reaffirmed with "ample room" to exceed the upper end ($340M) in Q4.
• Strategic Stance: Emphasis on "disciplined spending," "operating efficiency," and positioning for "longer-term growth" through technology and innovation.

Miscellaneous:

• Q4 Expectations: Management anticipates a "nice quarter" for the company, aiming to reach the higher end of the annual revenue range through Q4 2026.
• 2027 Guidance: No specific guidance provided for 2027; management indicated they will provide guidance for 2027 when reporting next quarter's results.
• Prostate Cancer AI Module: Internal testing on 262 cases identified 768 of 770 cancer-containing parts; currently undergoing pathologist evaluation.